Severe low molecular weight heparin-related bleedings. Two cases;Accidents hemorragiques graves lors d'un traitement par heparine de bas poids moleculaire. A propos de deux observations

Revue de Medecine Interne

Volumn 18, Issue 5, 1997, Pages 411-415

  Grateau, G ^a   Chauvenet, L ^a   Oudard, S ^a   Bachmeyer, C ^a   Capron, L ^a   Horellou, M H ^a   Samama, M M ^a  

^a HÔTEL DIEU   (France)

Author keywords

anti Xa activity; hemorrhage; low molecular weight heparin; risk factor for bleeding; venous thrombosis

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; BLOOD CLOTTING FACTOR 10A; FIBRINOLYTIC AGENT;

AGED; ARTICLE; BLEEDING; CANCER; CASE REPORT; DEEP VEIN THROMBOSIS; FATALITY; FEMALE; HEART FAILURE; HUMAN; KIDNEY FAILURE; MALE; OBESITY; RISK FACTOR; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; THROMBOPHLEBITIS;

AGED; AGED, 80 AND OVER; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; RISK FACTORS; THROMBOPHLEBITIS;

EID: 0031006670     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(97)82514-3     Document Type: Article

References (13)

1. Vitoux JF. Les héparines de bas poids moléculaire. Rev Méd Interne 1988;9:235-7
2. Samama MM. Surveillance biologique des traitements antithrombotiques. In: Samama MM, Acar J, éds. Les médicaments antithrombotiques. Paris: Masson, 1995:188-204
3. Lensing AW, Davidson BL, Prins MH, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-7
4. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison or efficacy and safety of low molecular weight heparins and unfractioned heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br Med J 1994; 309:299-304
5. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin). Results of a double-blind randomized study. Circulation 1989;80:935-40
6. Levine M, Gent M, Hirsch J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81
7. Koopman MMW, Pradoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hsopital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7
8. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-13
9. Campbell NRC, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Aging and heparin-related bleeding. Arch Intern Med 1996;156:857-60
10. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;78:2337-43
11. Toulemonde F, Doutremeprich C. Low molecular heparins and hemorrhage. In: Doutremeprich C, ed. Low molecular weight heparins in clinical practice. New York: Marcel Dekker, 1995:171-98
12. Ahlenc-Gelas M, Jestin-Le Guernic C, Vitoux JF et al. Adjusted versus fixed doses of the low molecular weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994;71:698-702
13. Schafer AI. Low-molecular-weight heparin. An opportunity for home treatment of venous thrombosis. N Engl J Med 1996;334:724-5